These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9271000)

  • 1. Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis.
    Kunova A; Trupl J; Demitrovicova A; Jesenska Z; Grausova S; Grey E; Pichna P; Kralovicova K; Sorkovska D; Krupova I; Spanik S; Studena M; Koren P; Krcmery V
    Microb Drug Resist; 1997; 3(3):283-7. PubMed ID: 9271000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole.
    Kunová A; Trupl J; Spánik S; Drgona L; Sufliarsky J; Lacka J; Studená V; Hlavácová E; Studená M; Kukucková E
    Chemotherapy; 1995; 41(1):39-44. PubMed ID: 7875020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome.
    Krcméry V; Spánik S; Grausová S; Trupl J; Krupová I; Roidová A; Sálek T; Sufliarsky J; Mardiak J
    Neoplasma; 1998; 45(5):336-42. PubMed ID: 9921924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
    Durán MT; Velasco D; Canle D; Moure R; Villanueva R
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):217-22. PubMed ID: 10212747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
    Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
    Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002.
    Wang JL; Chang SC; Hsueh PR; Chen YC
    J Microbiol Immunol Infect; 2004 Aug; 37(4):236-41. PubMed ID: 15340652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for fluconazole-resistant candidemia.
    Garnacho-Montero J; Díaz-Martín A; García-Cabrera E; Ruiz Pérez de Pipaón M; Hernández-Caballero C; Aznar-Martín J; Cisneros JM; Ortiz-Leyba C
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3149-54. PubMed ID: 20498325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study.
    Tan TY; Tan AL; Tee NW; Ng LS; Chee CW
    Mycoses; 2010 Nov; 53(6):515-21. PubMed ID: 19619263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
    Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
    Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
    Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia.
    Flórez C; Martín-Mazuelos E; Ruiz M; Cisneros JM; Herrero M; García MV; Márquez M; Porras J; Martín P; Gamero C; Castón JJ;
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):518-22. PubMed ID: 19477048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals.
    Zaoutis TE; Foraker E; McGowan KL; Mortensen J; Campos J; Walsh TJ; Klein JD
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):295-8. PubMed ID: 15922535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade.
    Parmeland L; Gazon M; Guerin C; Argaud L; Lehot JJ; Bastien O; Allaouchiche B; Michallet M; Picot S; Bienvenu AL;
    Med Mycol; 2013 Jan; 51(1):33-7. PubMed ID: 22680978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.